Leerink Partnrs Has Bullish Outlook for AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Aura Biosciences in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($1.67) per share for the year, up from their prior estimate of ($1.68). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.44) EPS, FY2025 earnings at ($1.93) EPS and FY2026 earnings at ($2.21) EPS.

Other research analysts have also issued reports about the stock. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Finally, BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 5.0 %

NASDAQ:AURA opened at $9.47 on Friday. The stock has a market capitalization of $473.04 million, a PE ratio of -5.47 and a beta of 0.33. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The firm has a fifty day simple moving average of $9.79 and a 200 day simple moving average of $8.51.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Institutional Trading of Aura Biosciences

Institutional investors have recently modified their holdings of the business. Levin Capital Strategies L.P. raised its position in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the period. American International Group Inc. increased its holdings in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares in the last quarter. Long Focus Capital Management LLC lifted its stake in Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Aura Biosciences during the 1st quarter worth approximately $144,000. Institutional investors own 96.75% of the company’s stock.

Insider Activity

In related news, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This represents a 15.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,259 shares of company stock worth $780,699. Corporate insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.